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Advancements in image-based technologies and body composition research over the past
decade has led to increased understanding of the importance of muscle abnormalities,
such as low muscle mass (sarcopenia), and more recently low muscle attenuation (MA),
as important prognostic indicators of unfavourable outcomes in patients with cancer.
Muscle abnormalities can be highly prevalent in patients with cancer (ranging between 10
and 90 %), depending on the cohort under investigation and diagnostic criteria used.
Importantly, both low muscle mass and low MA have been associated with poorer tolerance
to chemotherapy, increased risk of post-operative infectious and non-infectious complica-
tions, increased length of hospital stay and poorer survival in patients with cancer.
Studies have shown that systemic antineoplastic treatment can exacerbate losses in muscle
mass and MA, with reported loss of skeletal muscle between 3 and 5 % per 100 d, which
are increased exponentially with progressive disease and proximity to death. At present,
no effective medical intervention to improve muscle mass and MA exists. Most research
to date has focused on treating muscle depletion as part of the cachexia syndrome using
nutritional, exercise and pharmacological interventions; however, these single-agent therap-
ies have not provided promising results. Rehabilitation care to modify body composition,
either increasing muscle mass and/or MA should be conducted, and its respective impact
on oncology outcomes explored. Although the optimal timing and treatment strategy for
preventing or delaying the development of muscle abnormalities are yet to be determined,
multimodal interventions initiated early in the disease trajectory appear to hold the most
promise.
Sarcopenia: Muscle attenuation: Cancer: Cachexia: Body composition: Survival
Over the past decade, there has been a growing interest
in the measurement of body composition in patients
with cancer. This has largely been in response to
advancements in image-based technologies, including
gold standard computed tomography (CT) that allow
the precise quantification of both muscle and adipose
tissue. This research has led to increased understanding
of the importance of abnormal body composition
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phenotypes, such as low muscle mass (sarcopenia), and
more recently low muscle attenuation (MA) as important
prognostic indicators of unfavourable outcomes in
patients with cancer(1–4).
Cancer is a disease associated with ageing. As a result,
the aetiology of muscle loss in patients with cancer can be
two-fold. Firstly, resulting from the age-related decline in
muscle mass (sarcopenia), and secondly due to the meta-
bolic changes induced by malignancy and cancer cach-
exia. Muscle loss related to sarcopenia begins relatively
early in life, as muscle mass begins to decline from the
age of 40 at a rate of 6 % per decade(5) and accelerates
to a rate of 25–40 % per decade above age 70 years(6).
The precise definition of sarcopenia remains controver-
sial and a topic of much debate today; however, a gener-
ally accepted criterion in geriatric populations is a level
of muscle mass greater than two standard deviations
below that of a healthy young reference population(7).
Cancer cachexia is a multifactorial syndrome that is
characterised by the loss of muscle with or without the
loss of fat mass leading to progressive functional impair-
ment(8). It is driven by a variable combination of reduced
food intake and abnormal metabolism(8). Systemic
inflammation is commonly described as part of the
pathogenesis of cancer cachexia, and may suppress appe-
tite, increase body’s metabolic needs and energy expend-
iture, and accelerate muscle protein catabolism in
patients(8–10). Cancer cachexia represents a spectrum of
conditions and can range in severity and clinical presen-
tation from pre-cachexia, identified by early clinical and
metabolic signs (e.g. anorexia and impaired glucose tol-
erance) to refractory cachexia, where extensive muscle
and fat depletion is evident, and patients are often
immunocompromised(8). Recognition of these stages of
cachexia is important as these stages have different impli-
cations in the anabolic therapy response.
Reduced skeletal MA is a relatively newly charac-
terised and distinctive abnormality in patients with can-
cer(11). It represents a ‘qualitative’ measure of skeletal
muscle, as low radiation attenuation is reflective of intra-
muscular adipose tissue infiltration, and therefore, poor
‘quality’ skeletal muscle(11). It has been speculated that
low MA precedes the development of sarcopenia, as
the increase in lipid content occurs before a decline in
muscle mass(12,13). Importantly, in recent years, low
MA is emerging as an important prognostic indicator
in patients with cancer, and in some cases, a better prog-
nostic indicator compared with muscle mass alone(12–18).
Low muscle mass and low MA can occur at any given
BMI (kg/m2)(1,19), and now with 40–60 % of cancer pat-
ients presenting with overweight and obesity(20), identifi-
cation of these conditions is becoming increasingly
difficult. Patients may therefore not appear malnourished
as muscle depletion is often hidden behind mantles of
adipose tissue and can often go undiagnosed and untreated.
Body composition assessment is therefore crucial within
this patient group.
This review will focus on the diagnostic criteria, preva-
lence and clinical consequences associated with CT-
defined muscle abnormalities (low muscle mass and low
MA) in relation to chemotherapy tolerance, post-operative
outcomes and survival in oncology patients. We will
examine the changes in body composition that occur in
patients undergoing active anti-cancer treatment, and
finally, we will briefly examine the evidence behind cur-
rent treatments aimed at restoring muscle mass and
MA, with a particular emphasis on nutritional interven-
tions, physical activity, pharmacological agents and
multimodal treatments.
Measurement of skeletal muscle in oncology
The three most commonly used methods to measure body
composition in patients with cancer are bioelectrical
impedance analysis, dual-energy x-ray absorptiometry
and CT. Each technique has its advantages and disadvan-
tages, and methods differ in terms of cost, reliability, val-
idity, availability and training required(21). CT images are
considered a gold standard method for body composition
assessment, and allow the precise quantification of tissue
area, volume and attenuation. Unlike bioelectrical
impedance analysis or dual-energy x-ray absorptiometry,
CT can measure body composition at a tissue-organ level,
particularly total and regional adipose and skeletal
muscle tissues. The use of CT for body composition
assessment in non-cancer populations is limited by the
high radiation dose, high cost and lack of availability.
However, in oncology, CT scans are obtained routinely
during diagnostic and surveillance purposes, and there-
fore represent a unique and exploitable opportunity to
assess body composition within this patient group.
Measuring muscle mass by CT is usually done by
measuring total skeletal muscle area (SMA) at the third
lumber vertebra (L3). Using a commercially available
image analysis software (e.g. Sliceomatic (TomoVision),
OsiriX (Pixmeo), Image J (National Institutes of
Health), among others), muscle and adipose tissues can
be evaluated based on Hounsfield unit (HU) thresholds.
Muscles in this area include the psoas, paraspinal muscles
(erector spinea, quadratus lumborum) and the abdominal
wall muscles (transversus abdominus, external and
internal oblique, rectus abdominus). Measurements are
commonly taken at the third lumber vertebra, as the
SMA obtained at this level is a good correlate for whole
body muscle in healthy individuals (r 0·92)(22). From this
skeletal muscle index (SMI; total SMA (cm2)/height (m2))
can be calculated and patients are often compared on
this basis. Mean MA is typically derived by averaging
HU of the SMA at the third lumber vertebra. Although
SMI and MA are continuous variables and could be mod-
elled as such to predict survival/outcome, many clinicians
find the interpretation of continuous prognostic covariates
difficult, and prefer categorical or binary covariates based
on a threshold/cut point to stratify patients into distinct
risk groups when making treatment decisions.
Defining low muscle mass (sarcopenia) in patients with
cancer
Many oncological studies define sarcopenia based solely
on low muscle mass, and studies often lack information
on muscle strength or physical function. Therefore, the
criteria to define sarcopenia in this group differ from
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those proposed in geriatric populations(23,24). In the
oncology setting, consensus-based cut points to define
low muscle mass or sarcopenia are lacking, and a variety
have been devised. Studies(25–28) have defined sarcopenia
based on cut points developed by Baumgartner et al.(7) in
elderly individuals (2-SD below a healthy reference popu-
lation), by converting the original dual-energy x-ray
absorptiometry cut points (<7·26 kg/m2 for men and
<5·45 kg/m2 for women) to corresponding CT cut points
using published regression equations(29). These cut points
are SMI <55·4 cm2/m2 for men and <38·9 cm2/m2 for
women(29), and are those used in the cancer cachexia con-
sensus definition(8). To date, no healthy population refer-
ence values for muscle mass obtained from CT exist.
Studies have employed a statistical technique known as
optimal stratification, which is used to identify threshold
values associated with elevated risk of poor outcome
(e.g. mortality) to define sarcopenia. Using this technique,
Prado et al.(19) identified cut points for SMI that best pre-
dicted survival in a cohort of 250 obese (BMI >30 kg/m2)
cancer patients. These cut points are <52·4 cm2/m2 for
men and <38·5 cm2/m2 for women(19), and have been
widely applied in the literature. In 2013, Martin et al.(1)
identified both sex and BMI-specific cut points for SMI
that best predicted survival (men: <43 cm2/m2 if BMI
≤24·9 kg/m2 and <53 cm2/m2 if BMI ≥25 kg/m2;
women: <41 cm2/m2)(1) in a large cohort of 1473 patients
with lung and gastrointestinal (GI) cancer, which are
more applicable to non-obese cohorts. More recently, in
2017, Caan et al.(30) identified sex, BMI and cancer-
specific cut points for survival in a very large cohort of
early-stage colorectal cancer patients (n 3262; men:
<52·3 cm2/m2 if BMI <30 kg/m2 and <54·3 cm2/m2 if
BMI ≥30 kg/m2; women: <38·6 cm2/m2 if BMI <30 kg/m2
and <46·6 cm2/m2 if BMI ≥30 kg/m2)(30).
In addition to sex and BMI, ethnicity should be con-
sidered when applying cut points to a specific cohort.
Fujiwara et al.(31) defined CT-derived cut points for a
large (n 1257) homogenous cohort of Japanese patients
with mixed stage (I–IV) hepatocellular carcinoma that
best predicted survival (<36·2 cm2/m2 for men and
<29·0 cm2/m2 for women), providing a reference popula-
tion for these individuals. Notably, these cut points are
lower(31,32) compared with those derived from large
Caucasian populations(1,3,34).
Using optimal stratification methodology, several other
studies have reported cut points for SMI associated with
mortality in a number of cancer cohorts (see Table 1),
these range 36–55·8 cm2/m2 for men and 29–46·6 cm2/m2
for women. Several factors influence patient’s muscularity
(ethnicity, age, sex, physical activity and magnitude of adi-
posity)(35); hence, published cut points may not be applic-
able to all cancer populations. For example, cut points
published by Prado et al.(19) were devised in a cohort of
obese patients with cancer, and may have limited relevance
when applied to populations with varying prevalence of
obesity, but have subsequently been used in studies com-
prised of predominantly non-obese individuals(36–40).
Other studies have defined sarcopenia based on more
data-orientated approaches, dichotomizing SMI based on
predetermined percentiles, such as quartiles(41), tertiles(17,42)
or based on the median(43,44). Studies focused solely on
one muscle group, the psoas muscle, generating a psoas
muscle index, often considered patients within the lowest
quartile of psoas muscle index to be sarcopenic(45–47).
However, no studies have related psoas muscle area to
whole body measures, and it has only been weakly corre-
lated with total lumbar muscle area(48). Therefore, it has
been argued that the use of the psoas muscle as a sentinel
muscle for the diagnosis of sarcopenia is flawed(49). Other
investigations have included additional measures of phys-
ical function (hand grip strength and/or gait speed) in
conjunction with skeletal muscle from CT scan analysis
when defining sarcopenia in patients with cancer(50,51).
The rationale for including the measures of both muscle
mass and function is that muscle strength does not
depend solely on muscle mass, and the relationship
between muscle strength and mass is not linear(6).
Hence, several expert groups have proposed the use of
both muscle mass and function to define sarcopenia in
older adults(23,24,52).
Prevalence of low muscle mass (sarcopenia) in patients
with cancer
As discussed previously, comparison among studies
reporting the prevalence of sarcopenia is often difficult
because of inconsistent methodology used to evaluate
body composition (dual-energy x-ray absorptiometry,
bioelectrical impedance analysis, CT), and diagnostic
criteria/cut points used to define sarcopenia. Table 2 sum-
marises the prevalence of sarcopenia among patients with
cancer using the same methodology (CT defined SMI)
but using varying published cut points. The prevalence of
sarcopenia is highly variable across primary cancer sites,
and has been shown to range from 11 to 90 %(31,53). Of
note is the heterogeneity in the prevalence of sarcopenia
among cohorts of the same primary cancer site and
stage, e.g. 19–71 % in advanced colorectal cancer(54,55),
33–90 % in metastatic kidney cancer(53–56) and 21–89 %
in advanced pancreatic cancer(57,58). This large variability
could be attributed to the varying cut points used to
define sarcopenia; limitations related to sample size; or
patient characteristics such as age, sex, ethnicity, BMI
and concurrent co-morbidities, thus limiting the ability
to draw conclusions as to the true prevalence according
to the cancer site. Sarcopenia appears to be the most
prevalent in patients with any stage of pancreatic or
lung cancer, while in other cancer types (e.g. gastric
and breast), it appears to be more frequent in advanced
stage disease compared with earlier loco regional disease.
Sarcopenia can be present at any given BMI, and the
prevalence of sarcopenic obesity (sarcopenia and obesity
(BMI ≥30 kg/m2)) has been shown to vary between 1 and
29 % in studies including individuals from all BMI cat-
egories, and between 15 and 36 % in studies including
obese individuals only(59).
Low muscle attenuation in patients with cancer
Similar to the measures of SMI, no widely agreed upon
cut points are available for defining low MA. Martin
et al.(1) provided the first set of cut points for low MA
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(using optimal stratification) that related to poor
survival in a large cohort of lung and GI cancer patients
(n 1473; <41 HU for BMI <25 kg/m2 and <33 for BMI
≥25 kg/m2)(1). Since then, cancer-specific cut points for
low MA that relate optimally to survival have been
reported for lung(18,60), ovarian(61,62), periampullary(16),
pancreatic(63), gastro-oesophageal(28) and large B-cell
lymphoma(15). These range from <28·0 to 44·1 HU in
men(16,18,60) and <23·8 to 40·5 HU in women(16,18,60–62).
Other studies have defined low MA based on the sample
sex-specific median(44,64), tertile(17) or quartile(65).
The prevalence of low MA among patients with cancer
varies greatly, and is dependent on the cohort under
investigation and cut point used, but has been shown
to range from 10 to 86 %(18,66). Using the cut points
devised by Martin et al.(1), which have been applied
most widely in the literature, the prevalence of low MA
has been reported to be between 46 and 53 % in two
large cohorts of patients with cancer (mixed tumour
sites and stages (I–IV))(1,67). In the setting of advanced
disease, the prevalence of low MA has been reported to
be 33 % in melanoma(4), 55 % in pancreatic(68), 59 % in
gastric(13), 60 % in breast(14) and 86 % in prostate can-
cer(66), while in patients with operable colorectal cancer,
low MA is present in 58–78 % of patients(69,70).
Impact of muscle abnormalities on clinical outcomes
Notwithstanding the controversies in determining and
defining low muscle mass and low MA in oncology, it
has been well established and reported over the past dec-
ade that these muscle abnormalities are unequivocally
associated with negative clinical outcomes in patients
with cancer.
Muscle abnormalities and tolerance to chemotherapy
Chemotherapy can often be associated with severe
toxicity (grades III–IV) that can result in dose delays,
dose reductions and treatment termination, referred to
as dose-limiting toxicities (DLT). DLT may lead to hos-
pitalisations and can be life threatening. Exploratory
studies provided the initial evidence of an association
between low muscularity and increased incidence of
severe toxicity/DLT to chemotherapy, and subsequent
work has confirmed these observations in multiple cancer
sites and treatments (Fig. 1). In advanced disease, low
muscularity has been associated with poorer tolerance to
chemotherapy in patients with breast(71,72), renal(56,73,74),
liver(75), lung(76), colorectal(55,77), thyroid(78) andmelanoma
skin cancer(4,79). Sarcopenia, in patients with peritoneal
metastasis from colorectal cancer, was associated with
significantly more chemotherapy toxicities (57 v. 26 %,
P= 0·004) and particularly neutropenia (36 v. 17 %,
P= 0·04) in a cohort of 97 patients receiving hyperther-
mic intraperitoneal chemotherapy.
Even in early-stage disease (stages I–III), sarcopenia is
associated with poorer tolerance to chemotherapy(2,80–84).
Interestingly, in patients with early-stage breast cancer
(n 151) and receiving anthracycline- and taxane-based
chemotherapy, with every five-unit decrease in SMI, the
risk of any grade III–IV toxicity increased by 27 % (rela-
tive risk 1·27 (95 % CI 1·09, 1·49), P = 0·002)(82). In a
large study of patients with non-metastatic colon cancer
(n 533) treated with adjuvant FOLOX treatment,
patients with low muscle mass (lowest sex-specific tertile)
were twice as likely to experience dose reductions (OR
2·28,P = 0·01), dose delays (OR 2·24,P= 0·002) and early
discontinuation of treatment (OR 2·34, P = 0·03)(2).
Although the majority of studies have consistently
demonstrated an association between low muscle mass
and increased incidence of severe toxicity/DLT (twenty-
six of thirty-two studies; see Supplementary material
for summary of each study), fewer small studies found
contradictory findings(85–88).
Emerging data suggest low MA to be also associated
with poorer tolerance to antineoplastic agents(4,66,82). In
metastatic melanoma patients (n 84), we have previously
shown that patients with low MA more frequently
experienced high-grade toxicities (75 v. 31 %, P = 0·001)
and immune-related toxicities to ipilimumab (54 v. 23
%, P = 0·017) compared with those without low MA.
More importantly, these patients were more susceptible
to experience a DLT (37·5 v. 10·4 %, P = 0·011)(4). In
patients with metastatic prostate cancer treated with
Table 1. Cut points for skeletal muscle index (SMI) at the third lumber vertebra (L3) associated with mortality in patients with cancer
Author Country Tumour site/stage n Males SMI (cm2/m2) Females SMI (cm2/m2)
Prado et al.(19) Canada Respiratory and GI/stages I–IV* 250 <52·4 <38·5
Van Vledder et al.(54) The Netherlands Colorectal cancer with liver metastasis 196 <43·75 <41·1
Martin et al.(1) Canada Lung and GI/stages I–IV 1473 <43·0 (BMI <25 kg/m2)
<53·0 (BMI ≥25 kg/m2)
<41·0
Lanic et al.(33) France Diffuse large B-cell lymphoma 82 <55·8 <38·9
Iritani et al.(32) Japan Hepatocellular carcinoma/stages I–IV 217 ≤36·0 ≤29·0
Fujiwara et al.(31) Japan Hepatocellular carcinoma/stages I–IV 1257 <36·2 <29·6
Kimura et al.(161) Japan Lung cancer/stage III–IV 134 <41·0 <38·0
Choi et al.(57) Korea Pancreatic cancer/advanced 484 <42·2 <33·9
Coelen et al.(34) The Netherlands Perihilar cholangiocarcinoma/stages I–IV 100 <46·8 <39·1
Cann et al.(30) USA Colorectal cancer/stages I–III 3262 <52·3 (BMI <30 kg/m2)
<54·3 (BMI ≥30 kg/m2)
<38·6 (BMI <30 kg/m2)
<46·6 (BMI ≥30 kg/m2)
GI, gastrointestinal.
* Obese individuals only (BMI >30 kg/m2).
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Table 2. Prevalence of sarcopenia according to cancer site, country and definition used




Van Vledder et al.(54) The Netherlands Advanced/196 19 4
Lieffers et al.(110) Canada Stages II–IV/234 39 1
Thoresen et al.(162) Norway Advanced/50 20 1
Barret et al.(55) France Metastatic/51 71 2
Thoresen et al.(163) Norway and Canada Advanced/77 39 1
Miyamoto et al.(41) Japan Stages I–III/220 25 6
Reisinger et al.(164) The Netherlands Stages I–IV/310 48 1
Buskermolen et al.(88) The Netherlands Metastatic/67 57 3
Chemama et al.(77) France Advanced/97 40 3
Malietzis et al.(165) UK Resectable/763 65 3
Cann et al.(30) USA Stages I–III/3262 42 12
McSorley et al.(69) UK Resectable/322 47 3
Oesophageal/oesophagogastric cancer
Awad et al.(118) UK Stages I–III/47 57 1
Yip et al.(85) UK Stages I–III/35 26 1
Reisinger et al.(119) The Netherlands Stages I–IV/123 56 1
Tamandl et al.(28) Austria Non-metastatic/200 65 2
Tan et al.(84) UK Stages I–III/89 49 1
Anandavadivelan et al.(83) Sweden Resectable/72 43 1
Grotenhuis et al.(166) The Netherlands Resectable/120 45 1
Nishigori et al.(167) Japan Resectable/199 75 1
Elliott et al.(40) Ireland Resectable/252 16 1
Gastric cancer
Tegels et al.(168) The Netherlands Stages I–IV/152 58 3
Hayashi et al.(13) Japan Advanced/53 70 3
Nishigori et al.(169) Japan Resectable/157 62 1
Palmela et al.(81) Portugal Stages II–III/48 23 3
Kudou et al.(170) Japan Stages I–III/148 28 3
Lung cancer
Baracos et al.(27) Canada NSC/stages III–IV/441 47 2
Stene et al.(37) Norway NSC/stages IIIb–IV/35 71 1
Arrieta et al.(171) Mexico NSC/metastatic/84 69 1
Kim et al.(101) Korea SC/stages I–III/149 79 2
Kidney cancer
Antoun et al.(73) France Metastatic/55 55 2
Antoun et al.(38) Canada Advanced/80 53 1
Huillard et al.(74) France Metastatic/61 53 2
Sharma et al.(96) USA Metastatic/93 29 3
Auclin et al.(53) France Metastatic/124 90 2
Cushen et al.(56) Ireland Metastatic/55 33 1
Pancreatic cancer
Tan et al.(95) Canada Advanced/111 56 1
Dalal et al.(36) USA Locally advanced/41 63 1
Di Sebastiano et al.(172) Canada Stages IIb–IV/50 48 2
Cooper et al.(125) USA Resectable/89 52 2
Rollins et al.(68) UK Advanced/228 61 3
Wesseltoft-Rao et al.(58) Norway Advanced/45 89 2
Choi et al.(57) Korea Advanced/484 21 7
Liver cancer
Mir et al.(75) France Advanced/40 28 2
Harimoto et al.(173) Japan Stages I–IV/186 40 4
Fujiwara et al.(31) Tokyo Mixed stages/1257 11 8
Iritani et al.(32) Japan Stages I–IV/217 11 9
Voron et al.(99) France Non-metastatic/109 54 1 + 2
Mixed cancer cohorts
Prado et al.(19) Canada Lung and GI/
Stages I–IV/250 obese
15 1
Martin et al.(1) Canada Lung and GI/
Stages I–IV/1473
41 3
Veasey-Rodrigues et al.(39) USA Mixed tumour sites/
Advanced/306
47 1
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docetaxel (n 63), a combination of both low muscle mass
and lowMAwas associated with an increased risk of DLT
(59 v. 29 %, P= 0·021)(66). Similarly, in early-stage disease,
Shachar et al.(82) demonstrated that in breast cancer (n
151), the risk of hospitalisations due to chemotherapy tox-
icity increased 19 % with every five-unit decrease in MA
(relative risk 1·19 (95 % CI 1·00, 1·43), P= 0·05).
Increased toxicity in patients with sarcopenia may be
attributed to alterations in the distribution, metabolism
and clearance of systemic chemotherapy drugs(80). The
practice of administration of cytotoxic chemotherapy
based on body surface area, and targeted therapy as a
flat dose, ignores several sources of inter-individual vari-
ation. Using body surface area as the only method to
individualise chemotherapy drug dose is insufficient to
avoid severe toxicity, but the continued use mainly relies
on the lack of other more precise methods for dose indi-
vidualisation(89). It is recently acknowledged that vari-
ability in body composition (lean mass, fat mass and
total body water) of cancer patients may be a source of
disparities in the metabolism of cytotoxic agents resulting
in increased toxicity(73,80,90). The rationale is that body
weight comprises two major compartments, lean mass
and fat mass, which may be the two major sites of distri-
bution of hydrophilic and lipophilic drugs, respect-
ively(80,91). Therefore, changes in body composition
may lead to changes in the volume of distribution and
adversely impact the effectiveness and tolerance of can-
cer therapies.
Administration of hydrophilic chemotherapy drugs
that are mainly distributed to the lean mass compartment
in sarcopenic patients would result in a disproportionally
small volume of the drug distribution in relation to their
body weight or body surface area(71,80). This has been
hypothesised to lead to considerable variation in milli-
gram of chemotherapeutic agent per kg lean mass, and
a higher dose per kg lean mass is associated with more
frequent severe toxic side effects(76,80,92,93). In patients
with advanced non-small-cell lung cancer (n 424), when
the dose of non-platinum drugs was expressed as mg/kg
lean mass, a 3-fold range was observed, and the dose
of non-platinum chemotherapeutic agent per kg lean
mass was a significant predictor of haematologic toxicity.
Every 1 % increase in drug dose per kg lean mass above
the mean was associated with a 3 % increased risk of
grade III–IV haematologic toxicity, while patients with
Table 2. (Cont.)
Author Country Stage/n % Sarcopenic*
Sarcopenia
definition{
Daly et al.(127) Ireland Foregut/stage I–IV/225 40 3
Ní Bhuachalla et al.(67) Ireland Mixed tumour sites/stages I–IV/725 41 3
Breast cancer
Prado et al.(71) Canada Metastatic/55 26 1
Del Fabbro et al.(174) USA Loco regional/129 14 1
Shachar et al.(72) USA Metastatic/40 58 3
Rier et al.(14) The Netherlands Metastatic/166 67 3
Diffuse large B-cell lymphoma
Camus et al.(175) France NR/80//>70 years 55 5
Lanic et al.(33) France NR/82/>70 years 55 5
Other cancers
Moryoussef et al.(176) France GIST/advanced or high-risk resected/31 39 3
Fukushima et al.(103) Japan Urothelial/advanced/88 60 3
Psutka et al.(102) USA Urothelial/
Stages I–III/205
69 2
Cushen et al.(66) Ireland Prostate cancer/
Metastatic/63
47 3
Rutten et al.(43) The Netherlands Ovarian cancer/
Stages IIb–IV/123
50 10
Coelen et al.(34) The Netherlands Cholangiocarcinoma/stages I–IV/100 42 11
Daly et al.(4) Ireland Melanoma/metastatic/89 24 3
NSC, non-small cell; SC, small cell; GI, gastrointestinal; NR, not recorded; GIST, gastrointestinal stromal tumour.
* Prevalence of sarcopenia in both sexes combined.
{ Sarcopenia definitions stratified as follows:
1: Skeletal muscle index (SMI) <52·4 cm2/m2 for males; <38·5 cm2/m2 for females(19).
2: SMI <55·4 cm2/m2 for males; <38·9 cm2/m2 for females (Baumgartner sarcopenia cut points for elderly healthy subjects(7) converted to CT cut points using
regression equations(29).
3: SMI <43 cm2/m2 BMI ≤24·9 kg/m2 and <53 cm2/m2 for BMI >25 kg/m2 for males; <41 cm2/m2 for females(1).
4: SMI <43·75 cm2/m2 for males; <41·1 cm2/m2 for females(54).
5: SMI <55·8 cm2/m2 for males; <38·9 cm2/m2 for females(33).
6: SMI <49·5 cm2/m2 and for women <42·1 cm2/m2 (lowest quartile)(41).
7: SMI <42·2 cm2/m2 for males; <33·9 cm2/m2 for females(57).
8: SMI <36·2 cm2/m2 for males; <29·0 cm2/m2 for females(31).
9: SMI ≤36·0 cm2/m2 for males; ≤29·0 cm2/m2 for females(32).
10: SMI <41·5 cm2/m2 (median) for females(43).
11: SMI <46·8 cm2/m2 for males; <39·1 cm2/m2 for females(34).
12: SMI <52·3 cm2/m2 for men and <38·6 cm2/m2 for men with a BMI <30 kg/m2 and <54·3 cm2/m2 for men and <46·6 cm2/m2 for women with a BMI ≥30 kg/m2(30).
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doses >20 % above the mean were at almost double the
risk of experiencing a grade III–IV haematologic
toxicity(93). Pharmacokinetic data have supported this
hypothesis, with sarcopenic patients experiencing higher
plasma concentrations of antineoplastic drugs, and
experiencing more toxicity(75,78). The same hypothesis
holds true for toxicity to lipophilic drugs. In a study
of ovarian cancer patients receiving doxorubicin and
trabectedin, the risk of DLT decreased with increased
fat mass:lean mass ratio. As lipophilic drugs are mainly
distributed in the adipose tissue, leaner individuals
would present with reduced volume of distribution for
the drug and consequently increase their risk for
DLT(91).
In addition to the pharmacokinetic hypothesis to
explain the increased toxicity in sarcopenic patients,
other mechanisms have been suggested. Low levels of
lean mass and altered concentration of plasma proteins
(e.g. albumin) may affect the distribution of highly
protein-bound drugs, and may explain the increased
toxicity of the vandetanib(78), sorafenib(75) and epirubi-
cin(90). Systemic inflammation is known to inhibit hepatic
enzymes and may contribute to higher drug exposure,
and subsequently excess toxicity in patients with sarcope-
nia(75,78). In addition, sarcopenic patients are generally
more susceptible to acute medical events and perhaps
chemotherapy toxicity may be an additional generalised
intolerance(94). Whether altered chemotherapy dosing
based on lean mass in patients receiving treatment is
effective in preventing toxicity is currently being investi-
gated (ClinicalTrials.gov identifier: NCT01624051).
Sarcopenia and survival
The impact of sarcopenia on survival in oncology was
first identified in a cohort of 250 obese lung and GI can-
cer patients by Prado et al. in 2008(19). Within this study,
sarcopenic obese patients had a lower median overall sur-
vival compared with their non-sarcopenic counterparts
(11·3 v. 21·6 months, P< 0·001), and sarcopenic obesity
independently predicted survival when adjusted for
known prognostic covariates (hazard ratio (HR) 4·2
(95 % CI 2·4, 7·2), P< 0·0001)(19). Since then, sarcopenia
has repeatedly been shown to be independently prognos-
tic of reduced survival in a number of cancer sites and
stages including pancreatic(95), kidney(96,97), liver(98–100),
lung(101), oesophageal(28), colorectal(41,54,70), urothe-
lial(102,103) and lung and GI cancers(1). Its important
prognostic ability was reported in a study of 196 patients
following resection for colorectal cancer liver metastases,
whereby sarcopenic patients had a median survival of 24
months, which was in stark contrast to 60 months in
those without sarcopenia (P < 0·001)(54). In patients
with hepatocellular carcinoma (n 116), similar results
were obtained with a median survival of 16 months in
patients with sarcopenia compared with 28 months in
those without sarcopenia (P = 0·003)(98). More recently,
a large cohort of stage I–III colorectal cancer patients
Fig. 1. Sarcopenic patients experience more dose-limiting toxicities (DLT) to flurouracil (5-FU) in colon cancer(80);
capecitabine in breast cancer(71); sorafenib in renal cell carcinoma(73); 5-flurouracil, epirubicin, cyclophosphamide
(FEC) in breast cancer(90); sorafenib in hepatocellular carcinoma(75); sunitunib in renal cell carcinoma(74); vantetanib in
medullary thyroid cancer(78); fluropyramidine in colorectal cancer(55); phase I drugs in mixed cancer types(177); imatinib
in gastrointestinal stromal tumours (grade I–II toxicity)(176); epirubicin, cisplatin, capecitabine (ECX) and cisplatin,
5-flurouracil (CF) in oesophagogastric cancer(84); taxane-based chemotherapy (placitaxel, docetaxel, nab-paclitaxel) in
breast cancer(72); hyperthermic intraperitoneal chemotherapy (oxaliplatin and irrinotecan) in colorectal cancer(77),
neoadjuvant chemotherapy (NACT) (mixed types) in gastric cancer(81); ipilimumab in metastatic melanoma(4).
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(n 3262) showed that sarcopenic patients had a 27 %
higher risk of overall mortality than their non-sarcopenic
counterparts(30).
The impact of sarcopenia on survival has been exten-
sively reviewed previously(104–106) and of note is a recent
systematic review and meta-analysis(104), which examined
the prognostic value of sarcopenia in 7843 patients
with solid tumours from a total of thirty-eight studies.
Sarcopenia was found to be associated with poor overall
survival (HR 1·44 (95 % CI 1·32, 1·56), P < 0·001), the
effect of which remained in various tumour types and
across disease stages. Additionally, sarcopenia was asso-
ciated with cancer-specific survival (HR 1·93 (95 % CI
1·38, 2·70), P < 0·001), as well as disease-free survival
(HR 1·16 (95 % CI 1·00, 1·30), P = 0·014). However, it
is noteworthy to mention the limitations of this study.
The authors included several studies in the review that
contained duplicated data, and this is prohibited in a
meta-analysis as it may lead to overestimation of an
effect(107). In addition, the studies were largely heteroge-
neous in terms of the tumours considered, stage of disease,
treatments and cut points used to define sarcopenia, which
ranged from 29 to 42·1 cm2/m2 in women and 36 to 55·4
cm2/m2 in men(104).
In spite of the abundance of evidence supporting the
role of sarcopenia as an important and independent
prognostic factor in cancer, this finding has not always
been consistently reported and several studies have
reported no impact on survival(16–18,37,68,88). It is possible
that the impact of sarcopenia may vary depending on
cancer diagnosis, treatment and overall prognosis. For
example, in colorectal cancer patients, sarcopenia was
shown to be predictive of survival in patients undergoing
curative resection(41), but not in patients with unresect-
able disease receiving chemotherapy(108). Alternatively,
this may be a consequence of the choice of cut points
to define sarcopenia in many of these studies. As dis-
cussed earlier, cut points obtained in different studies
are highly dependent on the methodology and the popu-
lation from which they were devised, and when used in
dissimilar populations, they may represent a suboptimal
approach in identifying the true prevalence of low muscle
mass and its relationship to survival within these cohorts.
Muscle quality v. quantity
Low MA, often referred to as myosteatosis, is emerging
as an important prognostic indicator in patients with can-
cer and in some cases more superior to predicting sur-
vival compared with muscle mass alone(12–18). The first
report by Sabel et al.(109) in melanoma patients showed
poorer disease-free survival (P= 0·04) and distant
disease-free survival (P= 0·0002) in patients with the
lowest tertile of psoas MA. Antoun et al.(64) corroborated
these findings in a cohort of metastatic renal cell carcin-
oma patients, and reported that the median survival of
patients with a MA below the median (<38 HU in
men; <36 HU in women) was half that of those with
MA above the median (29 v. 14 months, P = 0·001). In
a large cohort of 1473 patients with lung and GI cancer,
Martin et al.(1) reported that patients with a MA below
the identified cut point (<41 HU for BMI <25 kg/m2
and <33 HU for BMI ≥25 kg/m2) were at a 36 %
increased risk of mortality (HR 1·36 (95 % CI 1·19,
1·55), P < 0·001). Recently, low MA has been shown
to be prognostic of reduced survival in a variety of differ-
ent tumours, including lung(18,60), kidney(64), breast(14),
gastric(13), pancreatic(17,65), periampullary(16), cholangio-
carcinoma(68), lymphoma(12,15) and melanoma(109). In a
cohort of 734 patients with advanced lung cancer,
Sjøblom et al.(18) reported that even minor changes in
MA are associated with mortality risk. An incremental
increase of 1 HU was associated with a 2 % reduction
in the risk of death (HR 0·98 (95 % CI 0·97, 0·99), P<
0·001). Accordingly, the mortality risk reduction of a 5
HU and 10 HU increase in MA were 8 % and 16 %,
respectively(18).
Sarcopenia, low muscle attenuation and post-operative
outcomes
Sarcopenia has also been identified as a predictor of
post-operative infections, complications, readmissions,
longer length of hospital stay and higher health care
costs(3,100,110–114). Elliott et al.(40) demonstrated that sar-
copenia, in a cohort of 252 patients with oesophageal
cancer undergoing resection, was independently asso-
ciated with increased risk of major postoperative compli-
cations (grade ≥IIIb; OR 5·30 (95 % CI 1·94, 14·45), P=
0·001) and pulmonary complications (OR 2·17 (95 % CI
1·12, 4·23), P= 0·023). Similarly, in patients with colorec-
tal cancer undergoing cytoreductive surgery for periton-
eal carcinomatosis (n 206), sarcopenia was associated
with severe post-operative complications, and sarcopenic
patients underwent significantly more reoperations (26 v.
12 %, P = 0·012)(3). Consequently, length of hospital stay
has shown to be significantly longer in patients with sar-
copenia(40,46,96,110,111,115). Following colorectal cancer
surgery (n 234), the length of hospital stay for sarcopenic
patients was 15·9 d compared with 12·3 d in patients
without sarcopenia (P = 0·038)(110). Ultimately, adverse
post-operative outcomes in patients with sarcopenia lead
to increased health care costs. In a Western-Europe
healthcare system, sarcopenia was independently asso-
ciated with increased hospital costs of €4061 per patient
(P= 0·015) in a study of 452 patients who underwent
cancer surgery of the alimentary tract(115).
Akin to sarcopenia, low MA is emerging as a predictor
of poor post-operative outcomes(16,44,109,116). In patients
with colon cancer undergoing open resection (n 91),
low MA was an independent risk factor for one or more
complications (P< 0·001)(44). Van Rijssen et al.(16)
reported similar findings, whereby patients with low
MA experienced significantly more major post-operative
complications (58 v. 37 %, P = 0·005) following resection
for periampullary cancer (n 166) compared with those
without low MA. Examining MA as a continuous vari-
able, Sabel et al.(109) reported that a 10 HU decrease in
psoas MA was associated with an 8·1 % increase in com-
plication rate in patients with stage III melanoma (n 101).
In line with this, low MA was associated with prolonged
length of hospital stay following colorectal cancer
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surgery in a large cohort of 805 patients (7 v. 6 d (P =
0·034))(70), and to a greater extent following pancreatic
cancer resection, whereby patients with low MA (post-
neoadjuvant chemoradiotherapy) had a mean length of
stay of 42 d compared with 23 d in those without
low MA (P = 0·001)(65).
Muscle loss during chemotherapy
The precision associated with CT analysis of body com-
position (1–1·5 %) has allowed recent investigations to
focus on the nature and magnitude of changes in body
composition during the disease trajectory in patients
with cancer. Studies have consistently shown that losses
in muscle mass and MA are exacerbated by antineoplas-
tic treatment(81,88,117–119). In oesophagogastric cancer
patients, neoadjuvant chemotherapy treatment which is
typically delivered over a 6–8-week period can decrease
SMA by 9·59 cm2 (P < 0·0001), which is the equivalent
to a loss of 2·9 kg of lean mass(118). These results have
been corroborated in a study of 252 oesophageal cancer
patients, whereby the prevalence of sarcopenia almost
doubled (15·9–30·8 %) during a course of neoadjuvant
chemotherapy(40).
In patients with cancer, muscle is lost at a very high
rate of 3–5 % per 100 d during systemic chemother-
apy(4,36,43,95), and losses are exponentially increased
with progressive disease and proximity to death(117,120).
In a recent study of metastatic colorectal cancer patients
(n 63), on average patients lost muscle at a rate of 6·1 %
during 3 months of chemotherapy(88); it is noteworthy
that the rate of decline is 24-fold more rapid than that
observed in healthy ageing adults who tend to lose mus-
cle at a rate of 1–1·4 % per year(6,121).
Alterations in muscle mass may be a consequence of
some cancer-directed therapies. Sorafenib, a multi-kinase
inhibitor, has been shown to provoke muscle wasting in
metastatic renal cell carcinoma patients, through the
downstream suppression of PI3K, AKTm and mTOR,
key mediators in activating muscle protein synthesis by
amino acids and other stimuli(38). Abiraterone(122) and
MK-0646 (anti-insulin-like growth factor 1 receptor)(123)
have also been reported to stimulate muscle loss through
maximal androgen suppression and inhibition of anti-
insulin-like growth factor 1 receptor, respectively. In
contrast, two chemotherapy agents (vandetanib and selu-
metinib) have resulted in significant muscle gain in
patients with advanced cancer(78,124).
Loss of muscle during systemic anti-cancer treatment
is associated with increased mortality in patients with
pancreatic(36,125), lung(37,126), colorectal(88,108), ovar-
ian(43), melanoma(4) and foregut cancer(127) (see Table 3
for a summary of available studies reporting that muscle
loss during treatment is prognostic of reduced survival).
Loss of muscle >2 %/100 d was independently associated
with reduced survival in ovarian cancer patients receiving
neoadjuvant chemotherapy (n 123; HR 1·77 (95 % CI 1·02,
3·09), P= 0·043)(43), and we have previously reported that
in patients with advanced cancers of the foregut, those
with a skeletal muscle loss >6 %/100 d are at more than
double the risk of mortality (HR 2·66 (95 % CI 1·42,
4·97), P = 0·002)(127). Importantly, skeletal muscle deple-
tion during chemotherapy has also been associated with
reductions in physical function in elderly patients with
advanced non-small-cell lung cancer (128).
Strategies to improve muscle mass and attenuation
Currently, there is no consensus treatment for attenuat-
ing or reversing the muscle wasting caused by sarcopenia
and/or cachexia in patients with cancer. Research to
date has focused on strategies to treat sarcopenia in the
context of cancer cachexia using nutritional, exercise
and pharmacological interventions. However, these
single-agent therapies have not provided promising
results, and perhaps multifaceted treatment strategies
may be more effective in treating cachexia. Ideally, inter-
ventions for cachexia should be initiated in the early
stages of weight loss (i.e. pre-cachexia); however, patients
are often referred for cachexia interventions late in their
disease trajectory (i.e. refractory cachexia). At this stage,
patients are in a catabolic state and respond poorly to
anti-cancer treatment(8). Experts have speculated that
the failure of treatments to show benefit at clinical evalu-
ation may not have been because of the drugs ability to
ameliorate or treat cancer cachexia, but because they
were introduced to patients too late(129).
Rehabilitation care to modify body composition,
either increasing muscle mass and/or MA should be con-
ducted, and its respective impact on oncology outcomes
explored. Previous investigations have shown that intra-
muscular adipose tissue was responsive to exercise in
non-cancer individuals(130), and that cancer patients
have anabolic potential(117). Current evidence in evaluat-
ing the efficacy of prehabilitation on postoperative out-
comes among cancer patients is still limited(131,132).
Future clinical trials are warranted to test whether the
window of time between cancer diagnosis and initiation
of treatment is an opportunity to commence interven-
tions to increase muscle mass and MA.
Nutritional interventions
A meta-analysis of oral nutritional interventions in
malnourished patients with cancer identified thirteen ran-
domised controlled trials and included 1414 patients. The
analysis, conducted by Baldwin et al.(133), concluded that
oral nutritional interventions had no significant effect on
body weight, energy intake or mortality compared with
standard care. Given the wide range of pathophysio-
logical alterations that occur in cancer, complex and
individualised targeted strategies incorporating modula-
tions of the metabolic components of cachexia (e.g.
inflammation) may be required to allow nutrition inter-
ventions to be more effective(134). To date, n-3 fatty
acids, such as EPA have received a lot of attention for
the treatment of cancer cachexia due to their potent anti-
inflammatory properties. In cancer, plasma n-3 fatty acid
levels appear to be depleted in patients with sarcopenia
and may contribute to accelerate muscle mass(135). The
results of several small clinical trials suggested that
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using EPA supplements or oral nutritional supplements
containing EPA in patients with advanced cancer
improved appetite, energy intake, body weight, lean
mass and/or physical activity(136–139). The n-3 fatty acid
supplementation has also been shown to be effective in
reducing intramuscular adipose tissue while maintaining
muscle mass (compared with standard care) in a small
cohort of patients with non-small-cell lung cancer(138),
supporting what is observed in preclinical experimental
animal models(140). However, the clinical evidence sup-
porting n-3 fatty acids remain inconclusive. Three sys-
tematic reviews published in 2007, 2009 and 2012
concluded that there was insufficient evidence to support
a recommendation for n-3 fatty acids to treat muscle
depletion and cancer cachexia(141–144). Due to the incon-
sistencies in the reported effects of n-3 fatty acids(145,146),
the ESPEN oncology nutrition guidelines issue only a
weak recommendation for their use to stabilise or improve
appetite, food intake, lean mass and body weight(144).
Achieving adequate protein intake is an essential com-
ponent to achieving muscle anabolism; however, no opti-
mal amino acid and protein requirements have been
established to prevent or treat sarcopenia in patients
with cancer. Current recommendations suggest intakes
of 1–1·5 g/kg/d in patients with cancer(144); however,
many patients fail to reach these requirements(147).
Moreover, recent research has suggested that protein
requirements should be based on the measures of lean
mass as opposed to body weight(148,149).
Physical activity
A recent meta-analysis(150) has shown resistance exercise
to be effective in increasing muscle strength and mass in










Median 104 d (IQR
97–112)
Median loss of skeletal muscle was 3·8 % per 100 d
(P = 0·003). Loss of skeletal muscle >3·8 % was
associated with poor OS (10·1 v. 16·3 months,
P = 0·02) on univariate analysis





Median 88 ± 22 d Mean reduction in SMA was 4·2 cm2 (95 % CI −7·3,
−1·9, P < 0·002) from baseline to follow-up. A trend
that loss of muscle >2 %was associated with reduced
survival (5·8 v. 10·7 months, P = 0·073)







Mean decrease in SMI was 1·2 cm2/m2 (P < 0·01).
Degree of muscle loss correlated with disease-free
survival (HR 0·89 (95 % CI 0·80, 1·00), P = 0·04), while
visceral adipose loss was associated with overall
survival (HR 0·97 (95 % CI 0·95, 0·99), P = 0·001) and
progression-free survival (HR 0·98 (95 % CI 0·96,










Median change in skeletal muscle was 4·2 %. Skeletal
muscle loss >5 % (highest quartile) independently










Median 78 d (IQR
67–92)
On average patients lost 6·1 % of SMA in 3 months.
Muscle loss >9 % (highest tertile) was significantly
associated with lower survival on multivariate analysis
(HR 4·47 (95 % CI 2·21, 9·05), P < 0·001)





84 d (SE ± 1·77) Mean change in SMAwas−5·2 ± 9·8 %/100 d . Change
in SM >2 % was significantly associated with reduced
survival on multivariate analysis (HR 1·77 (95 % CI







Mean 4·3 months Loss of SMA and SMI from baseline to follow-up scans
was 4·1 cm2 (P < 0·001) and 1·4 cm2/m2 (P < 0·001),
respectively. Decrease in SMI was associated with
poor survival (HR 1·063; P < 0·001)
Daly et al.(4) Melanoma/stage
IV/59
Ipilimumab Mean 146 ± 40 d Mean loss of SMA was 3·3 ± 5·8 %/100 d. A loss of
SMA >7·5 % was a significant predictor of overall
survival in multivariable (HR 2·1 (95 % CI 1·1, 4·6),
P = 0·046)




Median 118 d (IQR
92 to 158)
Mean loss of SMAwas 3·9 % (95 %CI−4·9,−2·8)/100
d. In patients receiving palliative chemotherapy (n 89),
a loss of SMA >6 %/100 d independently predicted
survival (HR 2·66 (95 % CI 1·42, 4·97), P = 0·002)
IQR, interquartile range; NSC, non-small cell; SM, skeletal muscle; SMA, skeletal muscle area; HR, hazard ratio; SMI, skeletal muscle index; SE, standard error;
OS, overall survival.
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cancer patients undergoing neoadjuvant and adjuvant
therapy, with mean increases in lower limb strength of
26·2 kg (P= 0·00001) and lean mass by 0·8 kg (P <
0·00001)(150). In a study of early-stage breast cancer
patients receiving adjuvant chemotherapy, resistance
exercise resulted in the reversal of sarcopenia and dyna-
penia in 43 and 59 % of patients, respectively(151). To
date, most studies have been conducted in early-stage
breast and prostate cancer and evidence of the effect of
physical activity on muscle mass and strength in patients
with advanced disease and cancer cachexia is lack-
ing(152,153). A recent Cochrane systemic review(153),
which aimed to examine the impact of exercise on lean
mass in patients with cancer cachexia, showed disap-
pointing results. The authors screened more than 3000
individual articles, but found no trials that met the inclu-
sion criteria for analysis(153). Initial findings indicate
that exercise is safe and well tolerated in patients with
advanced disease(154) and improves physical performance
and several domains of quality of life(155), but further
work is needed. Evidence of interventions aimed at
improving MA in patients with cancer are scarce; however,
evidence in older adults suggests that exercise may represent
a counter measure to improve MA, as studies have shown
that muscle fatty infiltration is amenable to change after 12
weeks of thrice-weekly resistance training(130).
Recently, a few studies have demonstrated that
exercise interventions are capable of improving cancer
outcomes. Cho et al.(156) reported that preoperative exer-
cise significantly improved operative risk factors and
decreased the frequency of serious postoperative compli-
cations in gastric cancer patients. In breast cancer, a
supervised moderate- to high-intensity exercise pro-
gramme during adjuvant chemotherapy was associated
with a beneficial effect on chemotherapy completion
rates with a significantly smaller proportion of patients
requiring dose adjustments compared with usual care
(12 v. 34 %)(157). The impact of exercise prehabilitation
on cancer outcome warrants further investigation.
Pharmacological agents
To date, no pharmacotherapies have been approved to
specifically treat the cancer cachexia syndrome. Non-
steroidal anti-inflammatory drugs have been suggested
as a potential treatment for cancer cachexia, with the
aim of reducing systemic inflammation. In a recent sys-
tematic review of thirteen studies, eleven showed either
improvement or stabilisation in weight or lean mass in
patients with cancer(158); however, the evidence is still
insufficient to recommend non-steroidal anti-inflammatory
drugs to treat cancer cachexia outside of clinical trials.
Promising results have been obtained for anamorelin (a
ghrelin receptor agonist); phase III trials (ROMANA 1
and ROMANA 2) have shown that anamorelin signifi-
cantly increases lean mass and improves anorexia/cach-
exia symptoms compared with placebo over a 12-week
intervention period. However, muscle function (measured
by hand grip strength) failed to improve during the
intervention(159). Food and drug administration regula-
tors generally require improvements in lean mass and
functional outcomes as co-primary endpoints for the
approval of new medications to treat cancer cachexia. As
a result, anamorelin has not received the food and drug
administration’s approval to date. Phase III trials have
recently been completed for enobosarm, a selective andro-
gen receptor modulator (NCT01355484), and MABp1,
an anti Il-1 α monoclonal antibody (NCT01767857), the
results of which are yet to be published.
Multimodal interventions
Results so far suggest that single-agent therapies may
be insufficient to counteract cancer cachexia and that
early multimodal interventions may be necessary to com-
bat its multifactorial and complex pathogenesis. A
multimodal approach including the use of individualised
nutritional interventions to promote energy balance and
ensure optimal protein intake, decreasing inflammation
and hyper metabolic stress with the aid of anti-
inflammatory agents (non-steroidal anti-inflammatory
drugs s and EPA) and increasing physical activity to
stabilise/increase muscle mass, strength and physical
performance has been recommended(134). One such inter-
vention currently under investigation is the MENAC
trial (Multimodal Exercise/Nutrition/Anti-inflammatory
treatment for Cachexia), whereby phase II feasibility
studies have yielded encouraging results and suggest
multimodal interventions are feasible and safe in patients
with cancer(160). The phase III trial (NCT02330926) is
currently being conducted across a number of inter-
national sites.
Conclusion
In summary, the evidence reviewed here shows that mus-
cle abnormalities are highly prevalent in adult patients
with cancer, across cancer sites and stages, and over-
weight and obesity do not preclude their presence.
However, the heterogeneity in the diagnostic criteria lim-
its the ability to accurately compare the reported preva-
lence rates between different cohorts and study findings
overall. Efforts are required to standardise muscle mea-
surements from CT images, as well as the diagnostic cri-
teria for sarcopenia and low MA in patients with cancer.
Nonetheless, the clinical importance of muscle abnor-
malities in these patients is evident, given their associa-
tions with negative clinical outcomes, such as poorer
tolerance to chemotherapy, increased risk of post-
operative complications and infections, increased length
of hospital stays and poor prognosis.
In an age of increasingly personalised medicine, CT
scans, obtained as part of routine patient care, provide
valuable individualised information on muscle mass
and MA with well-established prognostic implications.
Incorporating routine assessment of muscle abnormal-
ities from CT images into clinical practice has the poten-
tial to play a major role in stratifying patients at risk of
poorer clinical outcomes, who may benefit from targeted
interventions. At present, no effective medical interven-
tion to improve muscle mass and MA exists; however,
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in recent years, substantial progress has been made, with
the results of several clinical trials awaited in the near
future. The optimal timing and treatment strategy for
preventing or delaying the development of muscle abnor-
malities are yet to be determined, but multimodal inter-
ventions appear to hold the most promise.
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